 Quediapine, QP, is a second-generation short-acting antipsychotic drug which is extensively metabolized in the liver, resulting in decreased bioavailability. To overcome this issue, researchers developed an intravenous Quediapine, QP, albumin nanoparticle, NP, formulation to improve QP's antipsychotic activity and brain targeting. This formulation was designed using human serum albumin, HSA, as a carrier protein, and the optimal conditions were determined through various experiments. These included determining the optimal HSA concentration, pH, and stirring time to achieve a particle size of 103.54 nanometers and a Quediapine, QP, encapsulation efficiency of 96.32 percent. Additionally, the intravenous administration of the QP albumin NP resulted in increased brain targeting and reduced side effects, associated with the drug. Overall, these findings suggest that the QP albumin NP formulation can be used to improve QP's antipsychotic efficacy and brain targeting. This article was authored by HEND Mohammed Abdelbar, Allah S. Tulba, Haini W. Darwish, and others. We are article.tv, links in the description below.